Anti-TNF, a magic bullet in cancer immunotherapy?

Journal for ImmunoTherapy of Cancer

卷:7

Thomas Filleron¹  Nicolas Meyer²  Bruno Ségui²  Anne Montfort²  Carine Dufau²  Thierry Levade²  Céline Colacios²  Jean-Pierre Delord²  Maha Ayyoub²  Nathalie Andrieu-Abadie² 

[1] Biostatistics Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse;

[2] INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT);

关键词: Tumor necrosis factor;    Melanoma;    Anti-PD-1;    Anti-CTLA-4;    Infliximab;    Certolizumab;   

DOI  :  10.1186/s40425-019-0802-y

来源: DOAJ

【 摘 要 】

Abstract Immune checkpoint blockers (ICB) have revolutionized cancer therapy. However, complete response is observed in a minority of patients and most patients develop immune-related adverse events (irAEs). These include colitis, which can be treated with anti-tumor necrosis factor (TNF) antibodies such as Infliximab. In a recent issue of the Journal for ImmunoTherapy of Cancer, Badran et al. reported that co-administering Infliximab together with ICB to five cancer patients prevents colitis recurrence, with four of them exhibiting overall disease stability. The basis for this treatment strategy stemmed from our pre-clinical demonstration that TNF contributes to resistance to anti-PD-1 therapy. In agreement with this concept, we have shown that TNF blockers improve the anti-tumor therapeutic activity of ICB in mice and based on these findings we are currently evaluating the combination in melanoma patients enrolled in the TICIMEL clinical trial. Herein, (i) we discuss the scientific rationale for combining anti-TNF and ICB in cancer patients, (ii) comment on the paper published by Badran et al. and (iii) provide the TICIMEL clinical trial design.

【 授权许可】

Unknown